Abstract Number: 2294 • 2014 ACR/ARHP Annual Meeting
The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom
Background/Purpose: Systemic JIA (sJIA) treatment has changed dramatically with the introduction of biologic agents, although treatment approaches may differ between countries. We characterized and compared…Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…Abstract Number: 2301 • 2014 ACR/ARHP Annual Meeting
The New Proposal Classification Criteria for Juvenile Spondyloarthropaties
Background/Purpose Juvenile spondyloarthropathies (JSpA) are a group of rheumatologic diseases with a disease onset before 16 years of age and are characterized with enthesitis, lower…Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…Abstract Number: 2286 • 2014 ACR/ARHP Annual Meeting
Food Allergy and Celiac Disease in Children with Juvenile Idiopathic Arthritis
Background/Purpose: There are multiple strong associations between gut pathology and rheumatologic diseases. This connection, between primary GI disease and rheumatologic diseases, is manifest in both…Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…Abstract Number: 2290 • 2014 ACR/ARHP Annual Meeting
Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis
Background/Purpose Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes. American Academy of Pediatric guidelines recommend screening every 3 months in children with…Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…Abstract Number: 1866 • 2014 ACR/ARHP Annual Meeting
Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Background/Purpose: Although there is a higher frequency of adverse birth outcomes in women with rheumatoid arthritis, little is known on the subject regarding women who…Abstract Number: 276 • 2014 ACR/ARHP Annual Meeting
Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Background/Purpose: Elevated interleukin-6 (IL-6) levels have been associated with low growth velocity in patients with juvenile idiopathic arthritis (JIA).1 The efficacy of tocilizumab (TCZ), an…Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…Abstract Number: 284 • 2013 ACR/ARHP Annual Meeting
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Background/Purpose: The ACR has endorsed a core set of six measures to assess the course of JIA and the impact of treatment: active joint count,…Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…Abstract Number: 298 • 2013 ACR/ARHP Annual Meeting
Preliminary Prospective Study Of Ultrasonography In Patients With Juvenile Idiopathic Arthritis In Clinical Remission: Subclinical Synovitis May Predict Flare?
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and has variable prognosis, characterized by periods of activity and remission.…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »